EdwinPosadasMDFACP KM

PubMed

• Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
  Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, ...> ;The Journal of Urology. 2024 Apr 1
• Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis...
  Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, ...> ;The Journal of Urology. 2024 Apr 1
• Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after R...
  Todd M Morgan, Stephen A Boorjian, Mark K Buyyounouski, Brian F Chapin, David Y T Chen, Heather H Cheng, Roger Chou, Heather A Jacene, Sophia C Kamran, Sennett K Kim, ...> ;The Journal of Urology. 2024 Apr 1
• A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
  C Noel Bairey Merz, Aum J Solanki, Mitchell Kamrava, Edwin M Posadas, Stephen J Freedland, Leslie Ballas, Howard M Sandler, Katelyn M Atkins, Andriana P Nikolova> ;Cancer. 2024 Mar 26
• Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
  Ravi A Madan, Evan Y Yu, Edwin M Posadas, Richard J Lee, Fatima Karzai, Peter L Choyke> ;Journal of Clinical Oncology. 2024 Mar 15
• Variation in communication of side effects in prostate cancer treatment consultations.
  Gale, R., Luu, M., Friedrich, N., Venkataramana, A., Khodyakov, D., Spiegel, B., Daskivich, T., Naser-Tavakolian, A., Posadas, E., Sandler, H., Freedland, S.> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 23
• Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations.
  Aurash Naser-Tavakolian, Rebecca Gale, Michael Luu, John M Masterson, Abhishek Venkataramana, Dmitry Khodyakov, Jennifer T Anger, Edwin Posadas, Howard Sandler, Stephe...> ;Medical Decision Making. 2024 Apr 1
• 2 citations
  Genetic and biological drivers of prostate cancer disparities in Black men.
  Jun Gong, Daniel M Kim, Michael R Freeman, Hyung Kim, Leigh Ellis, Bethany Smith, Dan Theodorescu, Edwin Posadas, Robert Figlin, Neil Bhowmick, Stephen J Freedland> ;Nature Reviews. Urology. 2023 Nov 14
• Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
  Jun Gong, Daniel M Kim, Amanda M De Hoedt, Neil Bhowmick, Robert Figlin, Hyung L Kim, Howard Sandler, Dan Theodorescu, Edwin Posadas, Stephen J Freedland> ;Journal of Clinical Oncology. 2024 Jan 10
• ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
  Chen Qian, Qian Yang, Mirja Rotinen, Rongrong Huang, Hyoyoung Kim, Brad Gallent, Yiwu Yan, Radu M Cadaneanu, Baohui Zhang, Salma Kaochar, Stephen J Freedland, Edwin M ...> ;Biorxiv. 2023 Oct 12
• Relative search popularity of five advanced prostate cancer medications using Google Trends.
  Sanjay Das, Nadine A Friedrich, James Daniels, G Cecilia Galvan, Jun Gong, Edwin Posadas, William Aronson, Stephen J Freedland> ;Prostate Cancer and Prostatic Diseases. 2023 Sep 8
• 19 citations
  Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment.
  Zhijun Wang, So Yeon Kim, Wei Tu, Jieun Kim, Alexander Xu, Yoon Mee Yang, Michitaka Matsuda, Lien Reolizo, Takashi Tsuchiya, Sandrine Billet, Alexandra Gangi, Mazen No...> ;Cell Metabolism. 2023 Jul 11
• 4 citations
  Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs.
  Jasmine J Wang, Na Sun, Yi-Te Lee, Minhyung Kim, Tatyana Vagner, Krizia Rohena-Rivera, Zhili Wang, Zijing Chen, Ryan Y Zhang, Junseok Lee, Ceng Zhang, Hubert Tang, Jos...> ;Nano Today. 2023 Feb 1
• 3 citations
  Targeting Glutamine Metabolism in Prostate Cancer.
  Neil Bhowmick, Edwin Posadas, Leigh Ellis, Stephen J Freedland, Dolores Di Vizio, Michael R Freeman, Dan Theodorescu, Robert Figlin, Jun Gong> ;Frontiers in Bioscience. 2023 Jan 4
• 13 citations
  The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
  Martin Sjöström, Shuang G Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha, Arian Lundberg, Cameron Herberts, Adam Foye, Rahul Aggarwal, Junjie T Hua, Haolo...> ;Cancer Research. 2022 Nov 2
• 2 citations
  Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit.
  Bethany N Smith, Rajeev Mishra, Sandrine Billet, Veronica R Placencio-Hickok, Minhyung Kim, Le Zhang, Frank Duong, Anisha Madhav, Kevin Scher, Nancy Moldawer, Amy Oppe...> ;Molecular Therapy. 2023 Jan 4
• 13 citations
  HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.
  Na Sun, Ceng Zhang, Yi-Te Lee, Benjamin V Tran, Jing Wang, Hyoyong Kim, Junseok Lee, Ryan Y Zhang, Jasmine J Wang, Junhui Hu, Zhicheng Zhang, Manaf S Alsudaney, Kuan-C...> ;Hepatology. 2023 Mar 1
• Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE.
  Jun Gong, Edwin M Posadas> ;JNCI Cancer Spectrum. 2022 Jul 1
• 4 citations
  An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
  Soumyajit Roy, Nicholas G Zaorsky, Hilary P Bagshaw, Alejandro Berlin, Alison Tree, Sandra Turner, Bridget Koontz, Paul Nguyen, Ronald Chen, Robert T Dess, William C J...> ;International Journal of Radiation Oncology, Biology, Physics. 2022 Jun 1
• 1 citations
  Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
  Timothy J Daskivich, Rebecca Gale, Michael Luu, Aurash Naser-Tavakolian, Abhi Venkataramana, Dmitry Khodyakov, Jennifer T Anger, Edwin Posadas, Howard Sandler, Brennan...> ;The Journal of Urology. 2022 Aug 1
• 9 citations
  Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
  Na Sun, Yingying Yang, Hui Miao, Peter Redublo, Hongtao Liu, Wenfei Liu, Yen-Wen Huang, Pai-Chi Teng, Ceng Zhang, Ryan Y Zhang, Matthew Smalley, Peng Yang, Shih-Jie Ch...> ;Biosensors & Bioelectronics. 2022 Mar 1
• 2 citations
  First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
  Jacob J Adashek, Joshua J Breunig, Edwin Posadas, Neil A Bhowmick, Leigh Ellis, Stephen J Freedland, Hyung Kim, Robert Figlin, Jun Gong> ;Drugs. 2022 Mar 1
• 17 citations
  Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
  Yiwu Yan, Bo Zhou, Chen Qian, Alex Vasquez, Mohini Kamra, Avradip Chatterjee, Yeon-Joo Lee, Xiaopu Yuan, Leigh Ellis, Dolores Di Vizio, Edwin M Posadas, Natasha Kypria...> ;Nature Communications. 2022 Feb 3
• 1 citations
  Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples.
  Ruoxiang Wang, Nicholas N Nissen, Yi Zhang, Chen Shao, Chia-Yi Chu, Carissa Huynh, Edwin M Posadas, James S Tomlinson, Michael S Lewis, Stephen J Pandol> ;Frontiers in Physiology. 2022 Jan 1
• 12 citations
  A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression.
  Belinda L Sun, Lin Tang, Xiaoguang Sun, Alexander N Garcia, Sara M Camp, Edwin Posadas, Anne E Cress, Joe G N Garcia> ;Pharmaceuticals. 2021 Dec 17
• Join now to see all

Journal Articles

• Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer  
  Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM, Eur Urol., 1/3/2016
• Increased survival with enzalutamide in prostate cancer after chemotherapy  
  Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hains..., N Engl J Med, 1/1/2012
• Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials  
  Kim, H.L., Posadas, E.M., Figlin RA, Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic targets, 1/1/2011
• Chemotherapy for Central Nervous System Metastases in Renal Cancer: A Review  
  Chen, T., Posadas, E., Lukas, R., Kidney Cancer Journal, 1/1/2011
• Frontiers in Prostate Cancer: Telomeres and Cancer  
  Sommerfeld, H.J., Meeker, A.K., Posadas, E.M., Coffey, D.S., Cancer, 1/1/1995
• Synthesis and characterization of putrescinebased poly(phosphoester-urethanes)  
  Dahiyat, B. I., Hostin, E., Posadas, E. M. and Leong, K. W, Journal of biomaterials science, 1/1/1993
• Antiandrogen therapy in prostate cancer  
  Szmulewitz, R.Z., Posadas, E.M., Update on Cancer Therapeutics
• Join now to see all

Books/Book Chapters

• Principles and Practices of Oncology 
  Chapter: Molecular Biology of Prostate Cancer 
  Feng, F.Y., Chinnayan, A., Posadas, E.M.Editors: DeVita, Hellman, Rosenberg.2014
• Drug Management of Prostate Cancer. 
  Chapter: Calcitriol and Vitamin D analogs 
  Jensen, A.R., Szmulewitz, R.Z., Beer, T., Posadas, E.M.Editors: W. Figg and E. Small.2010
• Prostate Cancer: A Clinical Guide 
  Chapter: Management of Prostate Cancer Bone Metastases 
  Szmulewitz, R.Z., Posadas, E.M.Lippincott Williams & Wilkins2008
• Oncology-Hematology Source Book: Evidence-Based Principles 
  Chapter: Bladder Cancer 
  Posadas, E.M., Dahut WLEditors: Boyiadzis, Lebowitz, Frame, Fojo.Edition 1st,2007
• The Molecular Oncology of Prostate Cancer 
  Chapter: Angiogenesis and Angiogenesis Inhibitors 
  Posadas, E.M., Dahut WLEditors: J Ross, C Foster, Jones and Bartlett.2006
• Bethesda Handbook of Clinical Oncology 
  Chapter: Cervical Cancer 
  Posadas, E.M., Kotz, H.Edition 2nd,2005
• Proteomics in Cancer Research 
  Chapter: Protein arrays for clinical proteomics and signal transduction profiling. 
  Simpkins, F., Espina, V., Posadas, E., Petricoin, E., Liotta, L., Kohn ECEditors: D.C. Liebler.2005
• Principles and Practice of Gynecologic Oncology 
  Chapter: Chapter 4: tumor angiogenesis and metastasis 
  Posadas, E.M., Kohn ECEditors: W. Hoskins.Edition 4th,
• Join now to see all

Abstracts/Posters

• Very small nuclear circulating tumor cell (vsnCTC) as a putative biomarker for visceral metastasis in metastatic castration-resistant prostate cancer (mCRPC)
  Chen JF, Ho H, Hodara E, Go A, Ureno A, Kaufman ET, Sievert M, Chung LWK, Ke Z, Tseng HR, Posadas EM, J Clin Oncol, 1/1/2016
• A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cel...
  Huynh R, Chen JF, Tighiouart M, Sievert M, Oppenheim A, Moldawer NP, Knudsen B, Freeman M, Bhomowmick N, Rogatko A, Tseng HR, Cheng LWK, Scher K, Figlin RA, Posadas EM, J Clin Oncol, 1/1/2016
• A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mC...
  Autio KA, Garcia JA, Alva AS, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Summa JM, Youssoufian H, Scher HI, Dreicer R, J Clin Oncol, 1/1/2016
• A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
  Choueiri TK, Michaelson MD, Posadas EM, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP, J Clin Oncol, 1/1/2015
• Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castrationresistant prostate cancer (mCR...
  Posadas EM, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F., AACR, 1/1/2015
• Sub-classification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases
  Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Zhau H, Hous S, Ahmed RA, Luthringer DJ, Huang J, Li KC, Chung LWK, Ke Z, Tseng HR, Posadas EM, AACR, 1/1/2015
• Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
  Posadas EM, Chi KN, De Wit R, Jonge MJ, Attard G, Friedlander TW, Yu MK, Hellemans, P, Chien C, Abrams CC, Gonzalez M, Trudel GC, Chauhan V, Jiao JJ, Saad F, J Clin Oncol, 1/1/2015
• Subclassification of prostate cancer circulating tumor cells (CTCs) by nuclear size reveals very-small nuclear CTCs in patients with visceral metastases.
  Lu YT, Chen JF, Ho H, Lichterman J, Chung LWK, Li KC, Ke Z, Tseng HR, Posadas EM, J Clin Oncol, 1/1/2015
• Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
  NM Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram ..., J Clin Oncol, 1/1/2014
• A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC).
  Choueiri TK, Michaelson MD, Posadas EM, Sonpavde G, McDermott DF, Walsh MK, Wall KC, Seon BK, Jivani MA, Adams BJ, Theuer CP., J Clin Oncol, 1/1/2014
• Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
  Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Ping W, Kheoh T, Maul S, Smit JW, Gonzalez MD, Deporre P, Tran N, Nanus DM, J Clin Oncol, 1/1/2014
• A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastases with characterization of circulating...
  Posadas EM, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Ch..., J Clin Oncol, 1/1/2014
• A translational phase 2 study of cabozantinib in men with metastatic castration resistant prostate cancer with visceral metastasis with characterization of circulating...
  Posadas EM, Tighiouart M, Lu Y, Di Vizio D, Hoffman DJ, Green L, Scher K, Sievert M, Oppenheim A, Moldawer N, Knudsen B, Freeman M, Bhowmick N, Rogatko A, Tseng HR, Ch..., Annals of Oncology, 1/1/2014
• A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial
  NM Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrle, R Foster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, A Shivaram ..., J Clin Oncol, 1/1/2012
• Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant...
  Szmulewitz RZ, A. J. Wyche, Posadas EM, Stadler WM, J Clin Oncol, 1/1/2011
• Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastat...
  Stein MN, I. Khan, M. Hussain, G. Liu, G. Wilding, Posadas EM, Stadler WM, C. Jeyamohan, S. Eddy, R. S. DiPaola, J Clin Oncol, 1/1/2011
• A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consort...
  Ward JE, Karrison, T, Chatta G, Hussain M, Shevrin D, O'Donnell P, Szmulewitz RZ, Stadler WM, Posadas EM., J Clin Oncol, 1/1/2011
• Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy.
  Posadas EM, Tannir NM, Wong Y, Ernstoff MS, Kollmannsberger CK, Qian J, Ansell PJ, McKeegan EM, McKee MD, Ricker JL, Carlson DM, Michaelson MD, J Clin Oncol, 1/1/2011
• Tannir NM, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, Posadas EM, J. Qian, J. L. Ricker, D. Michaelson.
  Tannir NM, Y. Wong, C. K. Kollmannsberger, M. S. Ernstoff, D. J. Perry, L. J. Appleman, Posadas EM, J. Qian, J. L. Ricker, D. Michaelson., J Clin Oncol, 1/1/2010
• A randomized, double-blind, placebo-controlled phase II study of testosterone replacement in men with asymptomatic castrate-resistant prostate cancer (PC).
  Szmulewitz RZ, Posadas EM, B. Manchen, Stadler WM, J Clin Oncol, 1/1/2010
• Transient metastasis suppression by JNKK1/MKK4 in an experimental model of prostate cancer metastasis.
  Szmulewitz RZ, Tamara Lotan, Jennifer Taylor, Kristen Otto, Edwin M. Posadas, Carrie W. RinkerSchaeffer., Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009; Philadelphia, PA, 2009, 1/18/2009
• FYN knockdown results in altered cell morphology and motility in prostate cancer
  Saito YD., Jensen, A.R., Otto, K., Faoro, L., Jagadeeswaran, R., Salgia, R., Posadas EM, Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009; Philadelphia, PA, 2009, 1/18/2009
• Proteomic profiling of tumor and stroma from ovarian cancer biopsies taken before and during imatinib treatment show a pharmacodynamic relationship between receptor ph...
  Tchabo, N.E., Posadas EM., Kotz, H.L., Minasian, L., Chang, R., Steinberg, S., Kohn EC, Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, 1/1/2009
• Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA 180-086.
  Araujo J, P. Mathew, A.J. Armstrong, E.L. Braud, Posadas EM, M. Lonberg, G. Gallick, G.C. Trudel, P. Paliwal, C.J. Logothetis, European Journal of Cancer Supplements, 1/1/2009
• Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure.
  Tannir N, Y. Wong, C. Kollmannsberger, M.S. Ernstoff, D.J. Perry, L.J. Appleman, Posadas EM, J. Qian, J.L. Ricker, D.M. Michaelson, European Journal of Cancer Supplements, 1/1/2009
• Join now to see all

Lectures

• Intermittent vs. Continuous Androgen Deprivation Therapy 
  Ho Chi Minh City/Hanoi, Vietnam - 1/14/2016
• Blood-based biomarkers and precision oncology 
  Samuel Oschin Comprehensive Cancer Institute. Los Angeles, CA - 1/10/2016
• Circulating tumor cells versus circulating tumor DNA 
  Los Angeles, CA - 1/23/2015
• Immunotherapy of Genitourinary Malignancies. 
  Los Angeles, CA - 1/19/2015
• Urologic Oncology for OCNs 
  1/18/2015
• Advances in Medical Therapy for Prostate Cancer 
  Charles Drew University. - 1/12/2015
• Targeted therapy in Renal Cell Carcinoma. 
  1/7/2015
• Molecular Targets in Kidney and Bladder Cancer. 
  1/7/2015
• Circulating tumor cell nuclear sizes predict visceral metastasis in prostate cancer patients. 
  Shanghai, China - 1/5/2015
• Advancing Paradigms in Systemic Therapy for prostate cancer 
  1/5/2015
• Multidisciplinary Care in Prostate Cancer. 
  Huntington Hospital - 1/3/2015
• What happens when prostate cancer metastasizies? 
  1/26/2014
• Early Detection and Management of Prostate Cancer 
  1/18/2014
• Management of BRCA-associated prostate cancer. 
  CSMC - 1/13/2014
• Molecular analysis of circulating tumor cells in prostate cancer: moving toward a liquid biopsy and personalized medicine 
  1/10/2014
• Targeting metastasis in prostate cancer: Fyn and circulating tumor cells 
  City of Hope - 1/8/2014
• Prostate Cancer in African-American Men: What You Need to Know 
  1/8/2014
• Advances in Prostate Cancer therapy 
  1/6/2014
• Clinical perspectives in Translational Research 
  1/2/2014
• CTC technology in solid tumors. 10th World Congress on Urologic Research 
  Nashville, TN - 1/21/2013
• Management of Testicular Cancer in 2013 
  1/18/2013
• Targeting the c-MET pathway: Clinical Applications 
  1/9/2013
• Advances in Systemic Therapy for Prostate and Kidney Cancer 
  Siriraj Hopital/Mahidol University, Bangkok, Thailand - 1/5/2013
• Advances in Detection and Treatment of Prostate Kidney, and Bladder Cancer 
  Guam - 1/5/2013
• Clinical Trials vs. Standard Care: Exploring New Approaches in Cancer Treatment 
  1/18/2012
• Join now to see all